Stockreport

Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals, Inc.  (CNCE) 
Last concert pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.concertpharma.com/investor-relations
PDF CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing CohortsAdvancement into Phase 3 Evaluation Planned in 2020Company to Host Investor Confere [Read more]